NASDAQ: INDV · Specialty & Generic Drug Manufacturers
Indivior Pharmaceuticals (INDV) fair value and price range
As of 3 Oct 2026, Faircurve's model values Indivior Pharmaceuticals (INDV) at $35.86 a share. The stock last closed at $35.71, which puts the model's fair value 0.4% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 2 Oct 2026. Indivior Pharmaceuticals Inc.
Faircurve Insights · 3 Oct 2026
Indivior Pharmaceuticals Inc. operates as a holding company. It is primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence.
Faircurve's model found a fair value of $35.86 a share on 3 Oct 2026. This is the midpoint of 2,000 simulations. The previous run on 26 Sep 2026 gave $35.97, meaning the fair value moved -0.3%. The calibrated range over 63 trading days is $29.92 to $43.47. This range is built from the fair value, as there is no live options data for the stock, and it held the price 60% of the time at this horizon across 4,809 past valuations. The model grades the evidence behind this valuation as low.
The model compares Indivior Pharmaceuticals Inc. with Amneal Pharmaceuticals, Inc., Lantheus Holdings, Inc., Supernus Pharmaceuticals, Inc., and Elanco Animal Health Incorporated. Over the last 8 earnings reports, the stock moved around its earnings reports by a median size of 13.3%, ignoring direction. The moves include -8.8% on 3 Aug 2026 and +10.3% on 30 Apr 2026.
Written from the figures on this page for the 3 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give INDV?
The calibrated range for INDV over 63 trading days is $29.92 to $43.47. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,809 past valuations, refreshed 3 Oct 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $21.74 to $57.09. In 50% of the simulations the fair value came out above the price the model ran on.
How does INDV compare with similar companies?
The companies in specialty & generic drug manufacturers closest to Indivior Pharmaceuticals in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| AMRX Amneal Pharmaceuticals, Inc. | $20.30 | $18.90 | -6.9% | Fairly valued |
| LNTH Lantheus Holdings, Inc. | $99.96 | $99.94 | 0.0% | Fairly valued |
| ALKS Alkermes plc | $41.75 | $40.97 | -1.9% | Low evidence grade |
| SUPN Supernus Pharmaceuticals, Inc. | $42.38 | $46.93 | +10.7% | Fairly valued |
| ELAN Elanco Animal Health Incorporated | $22.14 | $21.11 | -4.7% | Fairly valued |
| ANIP ANI Pharmaceuticals, Inc. | $72.18 | $82.56 | +14.4% | Low evidence grade |
| PAHC Phibro Animal Health Corporation | $37.24 | $37.53 | +0.8% | Low evidence grade |
| AMPH Amphastar Pharmaceuticals, Inc. | $25.43 | $25.59 | +0.6% | Low evidence grade |
All specialty & generic drug manufacturer stocks ranked by gap to fair value
When does INDV report earnings, and how has the stock reacted?
Indivior Pharmaceuticals's next earnings report is scheduled for 29 Oct 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 7.8% in either direction through the nearest expiry, about 13 days out. That is the size the market is pricing, not a direction.
How INDV moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 13.3%.
| Report date | Two session move |
|---|---|
| 3 Aug 2026 | -8.8% |
| 30 Apr 2026 | +10.3% |
| 26 Feb 2026 | -2.7% |
| 30 Oct 2025 | +16.4% |
| 31 Jul 2025 | +21.0% |
| 24 Apr 2025 | +44.0% |
| 20 Feb 2025 | -22.5% |
| 24 Oct 2024 | +5.1% |
Indivior Pharmaceuticals at a glance
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence.
- Market value
- $4.5B
- Sector
- Healthcare
- Industry
- Specialty & Generic Drug Manufacturers
- Revenue expected, next twelve months
- $1.4B
- Consensus revenue growth, next fiscal year
- +7.5%
- Analysts with estimates
- 2
- Beta to the US market
- 0.38
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Indivior Pharmaceuticals on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 26 Sep 2026 the model's fair value for INDV was $35.97. As of 3 Oct 2026 it is $35.86, a change of -0.3%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Indivior Pharmaceuticals's valuation
Is Indivior Pharmaceuticals stock undervalued or overvalued?
Faircurve's model puts INDV's fair value at $35.86 a share against a last close of $35.71, as of 3 Oct 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is INDV's fair value?
$35.86 a share as of 3 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $21.74 to $57.09.
What price range does the model give INDV?
$29.92 to $43.47 over 63 trading days. Ranges built this way held the price 60% of the time across 4,809 past valuations, refreshed 3 Oct 2026.
When does Indivior Pharmaceuticals report earnings next?
The next report is scheduled for 29 Oct 2026. Companies can move their dates.
How much has INDV moved on past earnings reports?
Across its last 8 reports the median two session move was 13.3%, ignoring direction. The largest was +44.0% around the report of 24 Apr 2025.
How confident is the model in this valuation?
The model's evidence grade for INDV is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.